Lung and genitourinary pathology.
molecolar biology
121
Scopus Publications
Scopus Publications
Is there still a role for ureteric frozen section analysis during radical cystectomy? Attilio Barretta, Pietro Piazza, Calogero Catanzaro, Angelo Mottaran, Massimiliano Presutti, Amelio Ercolino, Fontanella Luca, Silvia Li Volsi, Francesco Romei, Fabrizio Scisciolo, Irene Corsini, Luca Muratori, Stefania La Rezza, Francesca Giunchi, Michelangelo Fiorentino, Cristian Vincenzo Pultrone, Hussam Dababneh, Francesco Chessa, Lorenzo Bianchi, Riccardo Schiavina BJU International, 2026 Objectives To evaluate the utility of routine intra‐operative frozen section analysis (iFSA) of distal ureteric margins during radical cystectomy (RC) for bladder cancer (BCa), focusing on diagnostic accuracy and oncological outcomes in a high‐volume tertiary centre. Patients and Methods We retrospectively identified 1081 patients with BCa treated with RC (2010–2024). Bilateral iFSA of the distal ureters was performed in all cases. Patients were stratified according to final distal ureteric margin status (positive vs negative); if positive, additional resections were attempted intra‐operatively. Diagnostic concordance between iFSA and final pathology was calculated. Kaplan–Meier curves were used to assess 5‐year upper urinary tract recurrence (UUTR) free‐survival, overall survival (OS), and cancer‐specific survival (CSS). Univariable logistic regression and multivariable logistic regression (MLR) models identified variables associated with positive margins. Results Overall, 139 patients (12.9%) had positive distal ureteric margins at iFSA. The sensitivity and specificity of FSA were 98.6% and 99.5%, respectively. In MLR models, hydronephrosis (odds ratio [OR] 1.75, P = 0.014), T3–T4 stage (OR 2.48, P = 0.003), bladder carcinoma in situ (CIS; OR 7.94, P < 0.001) and trigonal tumour location (OR 4.85, P < 0.001) were independently associated with positive distal ureteric margins at iFSA. Positive margins were associated with increased risk of UUTR (5‐year UUTR‐free survival: 58% vs 78%; P = 0.038), worse OS (5‐year OS: 48% vs 67%; P = 0.039), and worse CSS (5‐year CSS: 60% vs 75%; P = 0.0018). Conclusion Our study showed that iFSA of distal ureteric margins during RC for BCa provided excellent diagnostic performance and enabled cancer‐free anastomosis. Our findings support iFSA, especially in patients with bladder CIS, trigonal tumours, or hydronephrosis, to guide intra‐operative decisions and tailor postoperative surveillance.
Retrospective validation of an artificial intelligence system for diagnostic assessment of prostate biopsies on the ProMort cohort: study protocol Xiaoyi Ji, Renata Zelic, Oskar Aspegren, Nita Mulliqi, Michelangelo Fiorentino, Francesca Giunchi, Luca Molinaro, Sol Erika Boman, Kelvin Szolnoky, Luana Xuan Liu, Andreas Pettersson, Per Henrik Vincent, Martin Eklund, Olof Akre, Kimmo Kartasalo BMJ Open, 2025 Introduction Prostate cancer diagnosis and treatment planning depend on accurate histopathological assessment of needle biopsies, particularly through the Gleason scoring system. The inherently subjective nature of the grading creates variability between pathologists, potentially resulting in suboptimal patient management decisions. These reproducibility challenges extend beyond Gleason scoring to encompass other critical diagnostic and prognostic markers, including cancer volume quantification and detection of cribriform morphology patterns and perineural invasion. Artificial intelligence (AI) applications in digital pathology have emerged as promising solutions for enhancing diagnostic consistency and accuracy, with recent research demonstrating that automated systems can match expert-level performance in prostate biopsy evaluation. Nevertheless, comprehensive validation studies have revealed concerning limitations in model generalisability when deployed across different clinical environments and patient populations. Recent systematic reviews revealed widespread risk-of-bias limitations and insufficient external validation in AI diagnostic studies, highlighting critical needs for accumulated evidence supporting generalisability before clinical implementation. Rigorous external validation with preregistered protocols using independent datasets from diverse clinical settings remains essential to establish the reliability and safety of AI-assisted prostate pathology systems. Methods and analysis This study protocol establishes a framework for the retrospective external validation of an AI system developed for prostate biopsy assessment, to be conducted on the case-control samples of the National Prostate Cancer Register of Sweden, ProMort study (1998-2015). The primary aim is to evaluate the AI model’s diagnostic accuracy and Gleason grading performance using completely independent datasets separate from any model development or previously used validation cohorts. The diversity of the validation samples, spanning multiple geographic regions, temporal collection periods and reference standards, allows evaluation of model robustness across varied clinical contexts. Secondary aims encompass evaluating AI performance in cancer length estimation and detection of cribriform patterns and perineural invasion. This protocol delineates procedures for data collection, reference standard clarification and prespecified statistical analyses, ensuring comprehensive validation and reliable performance assessment. The study design conforms to established reporting guidelines Checklist for Artificial Intelligence in Medical Imaging (CLAIM) and Standards for Reporting Diagnostic Accuracy Studies using Artificial Intelligence (STARD-AI), and recognised best practices for AI validation in medical imaging. Ethics and dissemination Data collection and usage were approved by the Swedish Regional Ethics Review Board and the Swedish Ethical Review Authority (permits 2012/1586-31/1, 2016/613-31/2, 2019-01395, 2019-05220). The study adheres to the Declaration of Helsinki principles, and findings will be made available in open access peer-reviewed publications.
An open-source platform for structured annotation and computational workflows in digital pathology research Luca Lianas, Mauro Del Rio, Luca Pireddu, Oskar Aspegren, Francesca Giunchi, Michelangelo Fiorentino, Simone Leo, Renata Zelic, Per Henrik Vincent, Nicolas Destefanis, Daniela Zugna, Lorenzo Richiardi, Andreas Pettersson, Olof Akre, Francesca Frexia Scientific Reports, 2025 The rapid evolution of digital pathology has enabled large-scale data acquisition, driving sophisticated clinical research and advancing the development of AI-driven tools. These innovations have also revolutionised histopathological slide review, especially the annotation step (i.e. the process of marking specific areas of interest on glass-mounted tissue samples to add relevant clinical information) by digitising the process, enhancing precision and efficiency, and facilitating collaboration. However, currently available open-source annotation tools typically employ single-label approaches that provide a flat representation of whole-slide images (WSI), limiting their ability to capture the complexity of the diagnosis-significant elements in a detailed and structured way. Furthermore, the difficulty of strictly following precise review protocols and lack of provenance tracking during annotation processes can result in high variability and limit reproducibility and reusability of the collected data. In this work we present the CRS4 Digital Pathology Platform (CDPP), an open-source system for research studies that manages WSI collections and focuses on high-quality, structured annotations, gathered according to well-defined protocols. Its main features include: (1) structured, multi-label morphological and clinical image annotation; (2) support for controlled but customisable annotation protocols; (3) dedicated annotation tools to facilitate enhanced accuracy, efficiency and consistency in the annotation process; and (4) workflow-based computational analysis with integrated provenance tracking. We show how the platform has successfully supported three different studies, demonstrating the CDPP's ability to assist pathologists in the generation of high-quality annotated datasets, also suitable for reuse, in the context of digital pathology research.
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) Stefania Angelicola, Francesca Giunchi, Francesca Ruzzi, Mariateresa Frascino, Mary Pitzalis, Laura Scalambra, Maria Sofia Semprini, Olga Maria Pittino, Chiara Cappello, Irene Siracusa, Ilaria Candida Chillico, Martina Di Noia, Cristian Turato, Silvia De Siervi, Francesco Lescai, Teresa Ciavattini, Giulia Lopatriello, Luca Bertoli, Hugo De Jonge, Luisa Iamele, Annalisa Altimari, Elisa Gruppioni, Andrea Ardizzoni, Marzia Rossato, Francesco Gelsomino, Pier-Luigi Lollini, Arianna Palladini Journal of Translational Medicine, 2025 BACKGROUND: Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death worldwide. Although immune checkpoint inhibitors (ICIs) have shown remarkable clinical efficacy, they can also induce a paradoxical cancer acceleration, known as hyperprogressive disease (HPD), whose causative mechanisms are still unclear. METHODS: This study investigated the mechanisms of ICI resistance in an HPD-NSCLC model. Two primary cell cultures were established from samples of a NSCLC patient, before ICI initiation ("baseline", NSCLC-B) and during HPD ("hyperprogression", NSCLC-H). The cell lines were phenotypically and molecularly characterized through immunofluorescence, Western Blotting and RNA-Seq analysis. To assess cell plasticity and aggressiveness, cellular growth patterns were evaluated both in vitro and in vivo through 2D and 3D cell growth assays and patient-derived xenografts establishment. In vitro investigations, including the evaluation of cell sensitivity to interferon-gamma (IFN-γ) and cell response to PD-L1 modulation, were conducted to explore the influence of these factors on cell plasticity regulation. RESULTS: NSCLC-H exhibited increased expression of specific CD44 isoforms and a more aggressive phenotype, including organoid formation ability, compared to NSCLC-B. Plastic changes in NSCLC-H were well described by a deep transcriptome shift, that also affected IFN-γ-related genes, including PD-L1. IFN-γ-mediated cell growth inhibition was compromised in both 2D-cultured NSCLC-B and NSCLC-H cells. Further, the cytokine induced a partial activation of both type I and type II IFN-pathway mediators, together with a striking increase in NSCLC-B growth in 3D cell culture systems. Finally, low IFN-γ doses and PD-L1 modulation both promoted plastic changes in NSCLC-B, increasing CD44 expression and its ability to produce spheres. CONCLUSIONS: Our findings identified plasticity as a relevant hallmark of ICI-mediated HPD by demonstrating that ICIs can modulate the IFN-γ and PD-L1 pathways, driving tumor cell plasticity and fueling HPD development.
Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors Sofia Melotti, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Francesco Vasuri, Agnese Orsatti, Luisa Di Sciascio, Alessia Grillini, Eugenia Franchini, Francesco Massari, Veronica Mollica, Andrea Marchetti, Federico Mineo Bianchi, Maurizio Colecchia, Andres Martin Acosta, João Lobo, Michelangelo Fiorentino, Costantino Ricci American Journal of Clinical Pathology, 2025 Objective Several studies analyzed the “reprogramming” of germ cell tumors of the testis (GCTT), known to be an epigenetic process that results in the preservation of stem cell features and/or differentiation of GCTT. EZH2 is a methyltransferase involved in the epigenetic regulation of tumors and has become a promising therapeutic target, but few studies have analyzed its expression in GCTT, germ cell neoplasia in situ (GCNIS), and adjacent testis. Methods We tested 131, 36, and 29 GCTT components, GCNIS, and adjacent testes, respectively. EZH2 expression was evaluated by H-score and compared between different subgroups by adopting median values and the Fisher exact test. Results We found that EZH2 was more highly expressed by adjacent testis/GCNIS rather than by GCTT (P &lt; .001), with adjacent testis showing the highest values and being statistically significant compared to GCNIS (P &lt; .001). In adjacent testis, EZH2 expression was mainly detected in spermatocytes (primary and secondary) and spermatids, with scattered positive spermatogonia. Seminoma/embryonal carcinoma showed statistically significantly higher EZH2 expression compared to the other nonseminomatous GCTT (P = .027). Conclusions EZH2 is differentially expressed during GCTT reprogramming (adjacent testis [very high levels] → GCNIS [high levels] → seminoma/embryonal carcinoma [moderate levels] → other nonseminomatous GCTT [low/absent levels]), supporting its involvement in the epigenetic regulation for determining the fate of GCTT.
Storage Time and DNA Quality Determine BRCA1/2 Sequencing Success in Prostate Cancer: A Multicentre Analysis with Therapeutic Implications Mariavittoria Vescovo, Maria Rosaria Raspollini, Lorenzo Nibid, Francesca Castiglione, Eleonora Nardi, Dario de Biase, Francesco Massari, Francesca Giunchi, Francesco Pepe, Giancarlo Troncone, Umberto Malapelle, Mariantonia Carosi, Beatrice Casini, Elisa Melucci, Matteo Fassan, Luisa Toffolatti, Elena Guerini-Rocco, Federica Conversano, Alessandra Rappa, Stefania Tommasi, Claudio Antonio Coppola, Pio Zeppa, Alessandro Caputo, Sara Gaeta, Fabio Pagni, Davide Seminati, Andrea Vecchione, Stefania Scarpino, Daniela Righi, Chiara Taffon, Francesco Prata, Giuseppe Perrone Cancers, 2025 Background: Approximately 25.0% of metastatic prostate cancer patients harbour DNA damage repair mutations, including BRCA1 and BRCA2, which are actionable targets for poly(ADP-ribose) polymerase (PARP) inhibitors. Accurate detection of BRCA1/2 mutations is critical for guiding targeted therapies, but crucial pre-analytical factors, such as tissue storage duration and DNA fragmentation, drastically affect the reliability of next-generation sequencing (NGS) using real-world diagnostic specimens. Methods: This multicentre study analysed 954 formalin-fixed paraffin-embedded tissue samples from 11 centres, including 559 biopsies and 395 surgical specimens. This study examined the impact of storage duration (<1 year, 1–2 years, and >2 years) and DNA parameters (concentration and fragmentation index) on NGS success rates. Logistic regression and Cox regression analyses were used to assess correlations between these factors and sequencing outcomes. Results: NGS success rates decreased significantly with longer storage, from 87.8% (<1 year) to 69.1% (>2 years). Samples with higher DNA concentrations and fragmentation indexes had higher success rates (p < 0.001). Surgical specimens had superior success rates (83.3%) compared with biopsies (72.8%) due to better DNA quality. The DNA degradation rate was more pronounced in older samples, underscoring the negative impact of extended storage. Conclusions: Timely testing of BRCA1/2 mutations is critical for optimizing the identification of prostate cancer patients eligible for PARP inhibitors. Surgical specimens provide more reliable results than biopsies and minimizing the storage duration significantly enhances testing outcomes. Standardizing pre-analytical and laboratory procedures across centres is essential to ensure personalized treatments and improve patient outcomes.
Augmented Reality PSMA-3D guided robotic pelvic lymph node dissection (PLND) in prostate cancer patients L. Bianchi, A. Mottaran, B. Bortolani, L. Cercenelli, A. Farolfi, R. Scarlatti, P. Piazza, M. Ragni, M. Droghetti, F. Chessa, M. Salvador, C. Gaudiano, F. Giunchi, M. Barbagallo, A. Borriello, M. Fiorentino, P. Castellucci, C. Mosconi, E. Marcelli, S. Fanti, R. Schiavina, E. Brunocilla Prostate Cancer and Prostatic Diseases, 2025 Background and objective Intraoperative identification of suspicious lymph node metastases (LNM) detected at PSMA-PET is key to achieve optimal surgical outcomes of robot-assisted radical prostatectomy (RARP) with pelvic lymph node dissection (PLND). We aim to describe a novel technique of augmented reality (AR)-PSMA-3D guided PLND based on preoperative PSMA-PET for real-time identification of LNM. Methods Thirteen patients with high-risk PCa and miN1-2 or miM1a disease at PSMA-PET were prospectively enrolled. 3D segmentation model including suspicious LNM was created from PSMA-PET images. Intervention Patients underwent RARP with AR-PSMA-3D guided PLND for real-time intraoperative identification of suspicious LNM. Pathologic examination was used as reference standard. Key findings and limitations Four (30%) men had suspicious LNM at PSMA-PET outside the field of the PLND template. The AR-PSMA-3D guided PLND allow to dissect each region with suspected LNM at PSMA-PET with no intraoperative complications. Nine (69%) patients had pN1 disease and three (23%) men had nodal metastases outside the PLND template. The sensitivity, specificity, PPV, NPV and AUC of AR-PSMA-3D guided PLND at a per-region analysis were 69%, 90%, 52%, 95% and 0.79, respectively. Limitations: low spatial resolution of PSMA-PET for micro-metastases and the need for manual alignment of the 3D model. Conclusions and clinical implications AR-PSMA-3D guidance for PLND in patients with miN1-N2-M1a disease at PSMA-PET allows to facilitate the resection of suspicious LNM including those outside the PLND template. Patient summary We propose a novel technique combining AR and PSMA-PET 3D models to guide PLND during RARP in PCa patients. The AR-PSMA-3D guidance for PLND allows a promising real-time identification of suspicious nodes, even outside the PLND template.
Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer Nadia Boufaied, Paolo Chetta, Tarek Hallal, Stefano Cacciatore, Daniela Lalli, Carole Luthold, Kevin Homsy, Eddie L. Imada, Sudeepa Syamala, Cornelia Photopoulos, Anna Di Matteo, Anna de Polo, Alessandra Maria Storaci, Ying Huang, Francesca Giunchi, Patricia A. Sheridan, Gregory Michelotti, Quang-De Nguyen, Xin Zhao, Yang Liu, Elai Davicioni, Daniel E. Spratt, Simone Sabbioneda, Giovanni Maga, Lorelei A. Mucci, Claudia Ghigna, Luigi Marchionni, Lisa M. Butler, Leigh Ellis, François Bordeleau, Massimo Loda, Valentina Vaira, David P. Labbé, Giorgia Zadra Cancer Research, 2024
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT Costantino Ricci, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Alessia Grillini, Eugenia Franchini, Marco Grillini, Riccardo Schiavina, Francesco Massari, Veronica Mollica, Valentina Tateo, Federico Mineo Bianchi, Lorenzo Bianchi, Matteo Droghetti, Thais Maloberti, Giovanni Tallini, Maurizio Colecchia, Andres Martin Acosta, João Lobo, Kiril Trpkov, Michelangelo Fiorentino, Dario de Biase Virchows Archiv, 2023
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type Costantino Ricci, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Giorgia Di Filippo, Eugenia Franchini, Francesco Massari, Veronica Mollica, Valentina Tateo, Federico Mineo Bianchi, Maurizio Colecchia, Andres Martin Acosta, Michelangelo Fiorentino Histopathology, 2023
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis Sofia Melotti, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Giorgia Di Filippo, Eugenia Franchini, Francesco Massari, Veronica Mollica, Valentina Tateo, Federico Mineo Bianchi, Maurizio Colecchia, Andres Martin Acosta, João Lobo, Michelangelo Fiorentino, Costantino Ricci Pathology Research and Practice, 2023
Effectiveness of Radiomic ZOT Features in the Automated Discrimination of Oncocytoma from Clear Cell Renal Cancer Gianluca Carlini, Caterina Gaudiano, Rita Golfieri, Nico Curti, Riccardo Biondi, Lorenzo Bianchi, Riccardo Schiavina, Francesca Giunchi, Lorenzo Faggioni, Enrico Giampieri, Alessandra Merlotti, Daniele Dall’Olio, Claudia Sala, Sara Pandolfi, Daniel Remondini, Arianna Rustici, Luigi Vincenzo Pastore, Leonardo Scarpetti, Barbara Bortolani, Laura Cercenelli, Eugenio Brunocilla, Emanuela Marcelli, Francesca Coppola, Gastone Castellani Journal of Personalized Medicine, 2023
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma Costantino Ricci, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Maria Eugenia Maracci, Maria Sirolli, Agnese Orsatti, Federico Chiarucci, Eugenia Franchini, Matteo Borsato, Francesco Massari, Veronica Mollica, Federico Mineo Bianchi, Maurizio Colecchia, Andres Martin Acosta, Michelangelo Fiorentino Pathology Research and Practice, 2023
Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort Nicolas Destefanis, Valentina Fiano, Lorenzo Milani, Paolo Vasapolli, Michelangelo Fiorentino, Francesca Giunchi, Luca Lianas, Mauro Del Rio, Francesca Frexia, Luca Pireddu, Luca Molinaro, Paola Cassoni, Mauro Giulio Papotti, Paolo Gontero, Giorgio Calleris, Marco Oderda, Umberto Ricardi, Giuseppe Carlo Iorio, Piero Fariselli, Elena Isaevska, Olof Akre, Renata Zelic, Andreas Pettersson, Daniela Zugna, Lorenzo Richiardi Frontiers in Oncology, 2023
SOX2 and PRAME in the “reprogramming” of seminoma cells Agnese Orsatti, Maria Sirolli, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Eugenia Franchini, Marco Grillini, Francesco Massari, Veronica Mollica, Federico Mineo Bianchi, Maurizio Colecchia, Michelangelo Fiorentino, Costantino Ricci Pathology Research and Practice, 2022
The Use of Augmented Reality to Guide the Intraoperative Frozen Section During Robot-assisted Radical Prostatectomy Lorenzo Bianchi, Francesco Chessa, Andrea Angiolini, Laura Cercenelli, Simone Lodi, Barbara Bortolani, Enrico Molinaroli, Carlo Casablanca, Matteo Droghetti, Caterina Gaudiano, Angelo Mottaran, Angelo Porreca, Rita Golfieri, Daniele Romagnoli, Francesca Giunchi, Michelangelo Fiorentino, Pietro Piazza, Stefano Puliatti, Stefano Diciotti, Emanuela Marcelli, Alexandre Mottrie, Riccardo Schiavina European Urology, 2021
The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial Riccardo Schiavina, Matteo Droghetti, Giacomo Novara, Lorenzo Bianchi, Caterina Gaudiano, Valeria Panebianco, Marco Borghesi, Pietro Piazza, Federico Mineo Bianchi, Marco Guerra, Beniamino Corcioni, Michelangelo Fiorentino, Francesca Giunchi, Paolo Verze, Cristian Pultrone, Rita Golfieri, Angelo Porreca, Vincenzo Mirone, Eugenio Brunocilla Urologic Oncology Seminars and Original Investigations, 2021
Metabolomics of prostate cancer gleason score in tumor tissue and serum Kathryn L. Penney, Svitlana Tyekucheva, Jacob Rosenthal, Habiba El Fandy, Ryan Carelli, Stephanie Borgstein, Giorgia Zadra, Giuseppe Nicolò Fanelli, Lavinia Stefanizzi, Francesca Giunchi, Mark Pomerantz, Samuel Peisch, Hannah Coulson, Rosina Lis, Adam S. Kibel, Michelangelo Fiorentino, Renato Umeton, Massimo Loda Molecular Cancer Research, 2021
Secondary bladder amyloidosis due to Crohn's disease: a case report and literature review Matteo Droghetti, Amelio Ercolino, Pietro Piazza, Lorenzo Bianchi, Benedetta Fabbrizio, Francesca Giunchi, Federico Mineo Bianchi, Umberto Barbaresi, Carlo Casablanca, Elena Tonin, Angelo Mottaran, Michelangelo Fiorentino, Riccardo Schiavina, Eugenio Brunocilla Cen Case Reports, 2020
Is there a role for immunotherapy in prostate cancer? Alessandro Rizzo, Veronica Mollica, Alessia Cimadamore, Matteo Santoni, Marina Scarpelli, Francesca Giunchi, Liang Cheng, Antonio Lopez-Beltran, Michelangelo Fiorentino, Rodolfo Montironi, Francesco Massari Cells, 2020
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program David P. Labbé, Giorgia Zadra, Meng Yang, Jaime M. Reyes, Charles Y. Lin, Stefano Cacciatore, Ericka M. Ebot, Amanda L. Creech, Francesca Giunchi, Michelangelo Fiorentino, Habiba Elfandy, Sudeepa Syamala, Edward D. Karoly, Mohammed Alshalalfa, Nicholas Erho, Ashley Ross, Edward M. Schaeffer, Ewan A. Gibb, Mandeep Takhar, Robert B. Den, Jonathan Lehrer, R. Jeffrey Karnes, Stephen J. Freedland, Elai Davicioni, Daniel E. Spratt, Leigh Ellis, Jacob D. Jaffe, Anthony V. DʼAmico, Philip W. Kantoff, James E. Bradner, Lorelei A. Mucci, Jorge E. Chavarro, Massimo Loda, Myles Brown Nature Communications, 2019
Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer Svitlana Tyekucheva, Michaela Bowden, Clyde Bango, Francesca Giunchi, Ying Huang, Chensheng Zhou, Arrigo Bondi, Rosina Lis, Mieke Van Hemelrijck, Ove Andrén, Sven-Olof Andersson, R. William Watson, Stephen Pennington, Stephen P. Finn, Neil E. Martin, Meir J. Stampfer, Giovanni Parmigiani, Kathryn L. Penney, Michelangelo Fiorentino, Lorelei A. Mucci, Massimo Loda Nature Communications, 2017
Perineural invasion and risk of lethal prostate cancer Piotr Zareba, Richard Flavin, Masis Isikbay, Jennifer R. Rider, Travis A. Gerke, Stephen Finn, Andreas Pettersson, Francesca Giunchi, Robert H. Unger, Alex M. Tinianow, Swen-Olof Andersson, Ove Andrén, Katja Fall, Michelangelo Fiorentino, Lorelei A. Mucci Cancer Epidemiology Biomarkers and Prevention, 2017
Urinary biomarkers for prostate cancer Francesca Giunchi, Chiara Ciccarese, Rodolfo Montironi, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Holger Moch, Francesco Massari, Michelangelo Fiorentino Current Drug Metabolism, 2017
Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review Eleonora Farina, Fabio Monari, Giovanni Tallini, Andrea Repaci, Renzo Mazzarotto, Francesca Giunchi, Riccardo Panzacchi, Silvia Cammelli, Gilbert D. A. Padula, Francesco Deodato, Renato Pasquali, Stefano Fanti, Michelangelo Fiorentino, Alessio G. Morganti Endocrine Pathology, 2016
